Drug
Ivosidenib
Ivosidenib: highest development phase Phase 3, developed by Servier. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Servier
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ivosidenib 500mg Oral Tablet NCT05907057 | Phase 3 | Acute Myeloid Leukemia (AML) |
| Ivosidenib 500mg NCT06127407 | Phase 3 | Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen |
| Ivosidenib NCT05921760 | Phase 1/2 | IDH1-mutant Cholangiocarcinoma |
Latest
No recent events.
Follow Ivosidenib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.